Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 791 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Immunotherapy’s Role in Treating Endometrial Cancer Expected to Grow April 12, 2023 Woman Suffers Severe Eye Pain And Swelling, Finds Out She Has... April 17, 2019 Treatment Strategy for ecDNA-Driven Tumors Shows Potential December 5, 2024 Having Cancer as a Young Adult Put Me on a Path... May 25, 2021 Load more HOT NEWS Women Over Age 65 Years with Pathogenic Variants in Cancer Predisposition... ΚΑΡΚΙΝΟΣ ΤΩΝ ΟΣΤΩΝ Study Links Mental Health Treatment to Improved Cancer Survival New Study Finds Dogs Can Sniff Out Lung Cancer — And...
